Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 81,866 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 81,866 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $90.13, for a total transaction of $7,378,582.58. Following the transaction, the director directly owned 675,341 shares of the company’s stock, valued at $60,868,484.33. The trade was a 10.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Bruce Booth also recently made the following trade(s):

• On Friday, December 12th, Bruce Booth sold 678 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.04, for a total transaction of $61,725.12.
• On Thursday, December 11th, Bruce Booth sold 6,101 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.23, for a total transaction of $556,594.23.
• On Wednesday, December 10th, Bruce Booth sold 229,809 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.73, for a total transaction of $21,080,379.57.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR traded down $0.24 during midday trading on Wednesday, hitting $86.11. 1,043,150 shares of the stock traded hands, compared to its average volume of 809,415. The firm has a market capitalization of $7.03 billion, a P/E ratio of -23.40 and a beta of 2.20. Kymera Therapeutics, Inc. has a one year low of $19.44 and a one year high of $103.00. The firm has a 50-day moving average of $78.69 and a two-hundred day moving average of $66.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million during the quarter, compared to the consensus estimate of $14.80 million. During the same period in the previous year, the firm earned ($0.88) EPS. The business’s revenue was down 60.8% on a year-over-year basis. Equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on KYMR shares. Stephens increased their price objective on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Monday. Truist Financial increased their price target on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. B. Riley Financial lifted their price target on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Oppenheimer upped their price objective on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. Finally, UBS Group raised their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of KYMR. PNC Financial Services Group Inc. boosted its holdings in Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after buying an additional 770 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after acquiring an additional 424 shares in the last quarter. Larson Financial Group LLC boosted its stake in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after acquiring an additional 349 shares during the period. Osaic Holdings Inc. grew its position in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares in the last quarter. Finally, Bessemer Group Inc. raised its stake in Kymera Therapeutics by 652.0% during the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after purchasing an additional 815 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.